IndieBio

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

Xias Bio is a biotechnology company focused on producing recombinant proteins. It specializes in creating advanced soluble ingredients with improved attributes such as enhanced gel and film formation, and antioxidant properties. The company's core expertise lies in developing non-immunogenic natural motifs to deliver functionalities for research, beauty, and healthcare applications.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Bioeutectics develops and supplies high-performance, natural solvents for industrial processes. Utilizing eutectic technology and renewable resources, the company produces eco-friendly alternatives to petrochemical solvents, serving industries such as personal care, food ingredients, agro-tech, and green tech.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio is a biotechnology company focused on producing recombinant proteins. It specializes in creating advanced soluble ingredients with improved attributes such as enhanced gel and film formation, and antioxidant properties. The company's core expertise lies in developing non-immunogenic natural motifs to deliver functionalities for research, beauty, and healthcare applications.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Bioeutectics develops and supplies high-performance, natural solvents for industrial processes. Utilizing eutectic technology and renewable resources, the company produces eco-friendly alternatives to petrochemical solvents, serving industries such as personal care, food ingredients, agro-tech, and green tech.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that modulate RNA targets linked to cancer and neurodegenerative diseases. The company uses a proprietary platform that combines high-throughput screening, computational modeling, and machine learning with unique datasets to discover RNA-targeting compounds with potency and selectivity for traditionally inaccessible targets. Its approach includes RNA biosensor technologies that render target molecules detectable, aiding discovery and evaluation. Founded in 2021 and based in Seattle, Wayfinder aims to accelerate development of therapies for undruggable targets by enabling rapid screening and optimization of RNA-targeting small molecules.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Aima is a Vancouver-based company founded in 2019 that focuses on transforming the management of menstrual pain. The company provides a weekly proactive pain management system designed specifically for menstruators, offering personalized and effective solutions to address period pain. Aima's platform aims to empower users by enabling them to manage their pain with greater freedom and dignity. Through its innovative approach, Aima seeks to improve the overall experience of menstruators by providing accessible and tailored pain relief options.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

Bioeutectics develops and supplies high-performance, natural solvents for industrial processes. Utilizing eutectic technology and renewable resources, the company produces eco-friendly alternatives to petrochemical solvents, serving industries such as personal care, food ingredients, agro-tech, and green tech.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that modulate RNA targets linked to cancer and neurodegenerative diseases. The company uses a proprietary platform that combines high-throughput screening, computational modeling, and machine learning with unique datasets to discover RNA-targeting compounds with potency and selectivity for traditionally inaccessible targets. Its approach includes RNA biosensor technologies that render target molecules detectable, aiding discovery and evaluation. Founded in 2021 and based in Seattle, Wayfinder aims to accelerate development of therapies for undruggable targets by enabling rapid screening and optimization of RNA-targeting small molecules.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

AsimicA, founded by Nikolai Mushnikov and Grant Bowman in November 2018, specializes in developing innovative technologies aimed at enhancing production efficiency in microbial biosynthetic factories. The company's core focus is on improving yields of biosynthetic processes, a significant challenge in biotechnology due to relatively low product outputs. AsimicA's novel approaches, centered around microbial stem cell technology, have the potential to revolutionize the industry by enabling multi-fold increases in production efficiency, particularly for pharmaceutical biomolecules.

Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

Synthetix is a blockchain-based protocol facilitating the issuance of synthetic assets for derivatives trading in decentralized finance (DeFi). Established in Sydney, Australia in 2017 by Kain Warwick, it enables exposure to real-world assets like currencies and commodities on the blockchain.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Serenity Bioworks is a biotechnology company focused on developing innovative antibody mimetics for targeted protein degradation. The company employs advanced display techniques alongside computational methods to optimize the discovery process of these therapeutics. Additionally, Serenity Bioworks is engaged in creating gene therapies aimed at addressing underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative conditions. Their goal is to enhance the long-term efficacy and safety profiles of gene therapy treatments, ultimately improving patient outcomes with safer and more durable solutions.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Serenity Bioworks is a biotechnology company focused on developing innovative antibody mimetics for targeted protein degradation. The company employs advanced display techniques alongside computational methods to optimize the discovery process of these therapeutics. Additionally, Serenity Bioworks is engaged in creating gene therapies aimed at addressing underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative conditions. Their goal is to enhance the long-term efficacy and safety profiles of gene therapy treatments, ultimately improving patient outcomes with safer and more durable solutions.

MezoMax, Inc. is a biotechnology company based in San Francisco, California, founded in 2017. The company specializes in developing oral therapies aimed at accelerating the healing of nonhealing fractures and enhancing bone health. MezoMax's innovative approach involves a novel calcium gluconate stereoisomer that regulates calcium and mineral metabolism, facilitating faster bone fracture healing and improving treatment for osteoporosis, particularly in elderly patients. By focusing on preclinical orthopedics, MezoMax aims to provide a safer and more effective mechanism for stimulating bone-forming cells and addressing various bone diseases, including rare conditions linked to bone health.

Nivien Therapeutics is a biomedical company focused on developing medicines that enhance chemotherapy and immunotherapy for treatment-resistant cancers. Founded in 2016 and based in Boston, Massachusetts, the company has developed first small-molecule inhibitors targeting the Hippo signaling pathway, a mechanism implicated in cancer resistance. Its program aims to de-risk transfers of technology assets from leading research institutes and to build a platform that advances IO-chemo combination therapies, with an emphasis on expanding options for patients who do not respond to standard treatments.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Neurocarrus Inc. is a biotechnology company, established in 2017 and based in Lincoln, Nebraska, focused on developing innovative solutions for pain management. The company has engineered a novel, non-opioid therapeutic, known as N-001, which targets sensory neurons to effectively "freeze" pain signals before they reach the brain. This approach aims to provide pain relief that lasts longer than traditional opioids while avoiding the risks of addiction and muscular control disruption. Neurocarrus's technology addresses the needs of individuals suffering from chronic pain due to tissue injury, inflammation, or acute nerve damage, offering a vital alternative amid the ongoing opioid crisis. Additionally, the unique drug delivery platform developed by Neurocarrus holds potential for collaboration with other therapies aimed at sensory neuron-related medical needs. The company holds exclusive rights to both its therapeutic and delivery system across various applications.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Proteorex Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics for diseases with significant unmet medical needs. Founded in 2014 and based in Toronto, Canada, the company specializes in manufacturing small molecule drugs that target challenging diseases. Utilizing a proprietary platform technology, Proteorex integrates novel synthesis design strategies, computational modeling, and patient-derived cell-based screening to identify and develop new lead compounds. This approach enables the company to unlock druggable targets that have previously been considered undruggable, particularly in the field of oncology. Proteorex also maintains an office in San Francisco, further enhancing its capabilities in drug discovery and development.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative therapies for incurable cancers and neurodegenerative diseases. The company utilizes a machine vision and learning platform to drive diseased stem cells to non-diseased states by identifying drugs that induce epigenetic changes. Its proprietary Microscopic Imaging of Epigenetic Landscapes (MIEL) technology facilitates the discovery of small molecules capable of differentiating or reversing cancerous cells into benign types, potentially offering curative outcomes. Founded in 2017 and headquartered in San Diego, California, Stelvio Therapeutics combines scientific creativity, clinical excellence, and professional management to advance novel drug therapies and precision medicine diagnostics, with a particular emphasis on personalized treatments for conditions such as glioblastoma.

A2A Pharmaceuticals, Inc. is a biotechnology firm established in 2016 and based in New York, New York. The company is dedicated to developing innovative drugs aimed at treating antibiotic-resistant bacterial infections, tuberculosis, and cancer. A2A Pharmaceuticals employs a unique therapeutic design methodology focused on inhibiting protein-protein interactions while utilizing bioinformatics to target gram-negative bacterial species. The firm also incorporates advanced computational tools and interdisciplinary approaches, notably its SCULPT™ platform, which systematically constructs therapeutic candidates based on experimentally determined target characteristics. By advancing scientific research and delivering novel therapeutic agents, A2A Pharmaceuticals aims to address critical unmet medical needs and enhance treatment options for healthcare professionals.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Venomyx, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in developing and marketing innovative snake antivenoms, including the world's first toxin-specific snake antivenom. Venomyx aims to modernize antivenom treatment, making it safer, more effective, and more affordable for the millions of individuals affected by snakebites globally. Their focus on addressing the needs of underserved snakebite victims highlights their commitment to improving health outcomes in this critical area.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and headquartered in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that utilizes proprietary nanoparticles with unique multilayered structures. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's approach aims to enhance the specificity, efficacy, and safety of cancer treatments, offering healthcare providers new opportunities in the fight against cancer.

A2A Pharmaceuticals, Inc. is a biotechnology firm established in 2016 and based in New York, New York. The company is dedicated to developing innovative drugs aimed at treating antibiotic-resistant bacterial infections, tuberculosis, and cancer. A2A Pharmaceuticals employs a unique therapeutic design methodology focused on inhibiting protein-protein interactions while utilizing bioinformatics to target gram-negative bacterial species. The firm also incorporates advanced computational tools and interdisciplinary approaches, notably its SCULPT™ platform, which systematically constructs therapeutic candidates based on experimentally determined target characteristics. By advancing scientific research and delivering novel therapeutic agents, A2A Pharmaceuticals aims to address critical unmet medical needs and enhance treatment options for healthcare professionals.

Venomyx, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in developing and marketing innovative snake antivenoms, including the world's first toxin-specific snake antivenom. Venomyx aims to modernize antivenom treatment, making it safer, more effective, and more affordable for the millions of individuals affected by snakebites globally. Their focus on addressing the needs of underserved snakebite victims highlights their commitment to improving health outcomes in this critical area.

Scaled Biolabs Inc. is a biotechnology company based in San Francisco, California, specializing in research and development solutions for cell therapies. Established in 2016, the company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to facilitate the discovery of advanced cell-based medicines. This innovative platform allows leading biotech and pharmaceutical firms to explore a wide range of experimental parameters simultaneously, yielding valuable insights into cellular processes. By miniaturizing laboratory environments, Scaled Biolabs accelerates the development and manufacturing of novel cell therapies, which enhances clinical outcomes and reduces time to market. Additionally, the company is engaged in creating its own cell therapy assets, including a program focused on iPSC-derived dopaminergic neurons aimed at treating Parkinson’s disease.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and headquartered in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that utilizes proprietary nanoparticles with unique multilayered structures. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's approach aims to enhance the specificity, efficacy, and safety of cancer treatments, offering healthcare providers new opportunities in the fight against cancer.

Affinity Wulfrun is a United States-based company that has developed a technology platform aimed at reducing the manufacturing costs associated with biologics used in drug therapies and biosensors. In addition to its technological innovations, Affinity Wulfrun provides consulting services to address the scientific needs of its customers, positioning itself as a comprehensive resource for biologics manufacturing. The company's focus on streamlining production processes contributes to making biopharmaceutical development more cost-effective.

Affinity Wulfrun is a United States-based company that has developed a technology platform aimed at reducing the manufacturing costs associated with biologics used in drug therapies and biosensors. In addition to its technological innovations, Affinity Wulfrun provides consulting services to address the scientific needs of its customers, positioning itself as a comprehensive resource for biologics manufacturing. The company's focus on streamlining production processes contributes to making biopharmaceutical development more cost-effective.